WebMar 7, 2024 · IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0 Published by IDSA, 3/7/2024 A Focus on Extended-Spectrum β … WebThis manuscript reviews the management of SSTIs caused by carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa (CRPA), Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia. We also highlight a few novel antibiotics that show promise in the future management of MDR-GNB SSTIs. Recent findings:
Xerava (eravacycline) dosing, indications, interactions, adverse ...
Webwarfarin. eravacycline increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor. zinc. zinc will decrease the level or effect of eravacycline by cation … WebMar 2, 2024 · Eravacycline is increasingly utilized in MDR Gram-negative infections but has limited data to reflect its use in treatment of Stenotrophomonas infections [65]. In several series, the reported MICs ... dr. wrone north brunswick
IDSA Guidance on the Treatment of Antimicrobial …
WebFeb 1, 2024 · National Center for Biotechnology Information WebOct 25, 2016 · In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, … WebMar 21, 2024 · Abstract. Stenotrophomonas maltophilia is an underappreciated source of morbidity and mortality among gram-negative pathogens. Effective treatment options with acceptable toxicity profiles are limited. Phenotypic susceptibility testing via commercial automated test systems is problematic and no Food and Drug Administration breakpoints … dr wrone princeton